Skip to main content
. 2020 Sep 10;10(6):1397–1404. doi: 10.1007/s13555-020-00441-4

Fig. 3.

Fig. 3

Receiver operating characteristic curves for the week 4 Psoriasis Area and Severity Index (PASI) percentage improvement for predicting Dermatology Life Quality Index (DLQI) (0,1) and Itch Numeric Rating Scale (NRS) (0) response rates in patients treated with ixekizumab for 12 weeks. DLQI (0,1) represents an outcome of no effect of skin condition on patient’s quality of life and Itch NRS (0) represents complete resolution of itch. AUC area under the curve